Download
Download Image

Please provide your email to download the resource

    Executive Summary

    MedTech companies in 2025 face a more complex commercialisation landscape than ever before. They grapple with fragmented regulations, intense competition from new entrants, and pricing pressures from cost-conscious health systems. Traditional go-to-market approaches are struggling to keep pace; market data often comes in silos or outdated reports, leaving teams reactive instead of proactive.

    Artificial Intelligence (AI) is emerging as a transformative force to meet these challenges head-on. By harnessing AI-driven market intelligence, MedTech executives can convert vast, real-time data into actionable insights, enabling smarter market entry strategies and faster decision-making. Early adopters of AI in MedTech commercial operations are already seeing tangible benefits, from doubling the number of qualified leads to up to 10% increases in incremental revenue. This white paper explores how AI-powered market intelligence addresses key commercialisation hurdles and provides MedTech organisations a competitive edge in a rapidly evolving market.

    Authors

    Marcel G. Haan, MBA
    Founder & CEO, Foxfire MedTech

    Praful Mehta
    CEO & Co-founder, Vamstar

    Acknowledgements

    This white paper represents a strategic collaboration between Vamstar and Foxfire MedTech Academy, combining the expertise of both organisations to explore the transformative role of AI in MedTech commercialisation.

    We extend our sincere gratitude to Praful Mehta, CEO and Co-founder of Vamstar, and Marcel G. Haan, CEO and Founder of Foxfire MedTech, for their co-authorship and leadership in shaping this paper. Their combined vision—grounded in deep domain knowledge across AI, commercial strategy, and MedTech market dynamics—has been central to the insights and guidance shared throughout this document.

    We would also like to acknowledge Richard Charter, an esteemed industry expert in health economics, market access, and sustainability strategy, who joined Marcel as a co-host in the foundational webinar that inspired this white paper: “AI-Powered Market Intelligence in MedTech Commercialisation.” The session is available here and continues to serve as a valuable resource for commercial and market access leaders across the MedTech landscape.

    Together, this collaboration underscores our shared commitment to equipping MedTech professionals with the actionable frameworks, advanced technologies, and practical strategies required to thrive in an increasingly complex and competitive global market.

    Vamstar and Foxfire MedTech Academy are proud to contribute to the ongoing evolution of the sector—and to support organisations on their journey toward smarter, data-driven commercialisation.

    The Changing Landscape of MedTech Market Entry

    The MedTech market in 2025 is defined by high barriers to entry and fast-shifting dynamics.

    Regulatory hurdles loom large: companies must navigate a patchwork of global approval requirements and evolving compliance standards in each country. A recent analysis highlights that MedTech firms are contending with continually changing regulations and complex hospital contracting processes. Pricing challenges have intensified as healthcare payers push for value – governments and insurers use measures like price transparency rules and value-based care models to control costs. At the same time, competitive pressures are mounting. Leaders face an influx of new products and players, including startups and tech giants entering the medical device arena. Major incumbents are pursuing M&A at a record pace to expand their portfolios, further raising the stakes for market entrants.

    Traditional market entry methods are proving inadequate against this backdrop. In many organisations, market assessments rely on periodic reports, manual research, and gut feel from sales teams. These approaches struggle with scale and speed – for instance, one global investor noted that scanning diverse international markets was too complex and data-intensive for their traditional analysis methods. Such methods often leave commercialisation teams with blind spots. Important signals like a competitor’s new product launch or a subtle shift in reimbursement policy can be missed until it’s too late. In short, the old playbook of spreadsheets and annual field surveys cannot keep up with today’s fast-moving MedTech environment. This has created an urgent need for more agile, data-driven intelligence to guide market entry strategy.

    Case Study

    Real-World Insights for Accelerating MedTech Market Entry

    Unveiling Opportunity with AI-Driven Market Intelligence

    A fast-growing scale-up in the MedTech industry was gearing up to launch a groundbreaking interventional cardiology device. The technology was highly differentiated, yet its niche use-case posed a real challenge. Over the course of a year, the company had worked with a top-tier consulting firm to explore the size of the market, clinician preferences, procedure growth, and reimbursement rates—particularly focusing on the Big Five markets in Europe. Their extensive research resulted in a specific pricing strategy that the leadership team felt confident about.

    However, two months prior to launch, a senior team member encountered Vamstar and asked whether we could independently validate their pricing assumptions using our AI-driven market intelligence platform. This question—simple at first glance—sparked a journey that would reshape the company’s launch strategy and market success.

    Challenges

    1. Niche Use-Case & Market Uncertainty

      • Though the device was clinically innovative, its adoption potential remained hard to predict because of its relatively narrow application.
      • Existing research provided a snapshot of market size and procedure growth, but the company wanted more dynamic insights into competitive behaviour and future pricing trends.

    3. Complexity of European Markets

      • The consultancy work had primarily focused on the Big Five markets, but lacked deeper intelligence into procurement methods, payer models, competitive positioning, and shifting regulatory requirements.
      • Reimbursement pathways and innovation funding opportunities can differ considerably even between neighbouring countries.

    4. Lack of Real-Time Data

      • Traditional research methods can quickly become outdated.
      • With launch only two months away, the scale-up needed a rapid yet robust validation of its pricing strategy.

    Solution: Vamstar’s AI-Powered Market Intelligence

    1. Leveraging Vamstar’s platform, our team embarked on a comprehensive data-driven investigation:

      • Data Aggregation at Scale
        • We explored over 40 million tender records—including notices, awards, documents, briefs, and reports—providing unparalleled insight into procedure trends, payer preferences, and competitive positioning across the Top Ten EU markets.
        • This vast dataset was then filtered and structured, capturing detailed pricing movements, procedure patterns, and win-rate statistics.

    2. Primary & Secondary Research

      • To augment the data findings, our expert panel conducted targeted primary research on competitive intensity and clinicians’ openness to the new procedure.
      • We also performed secondary research on reimbursement frameworks, identifying existing incentives and new innovation funding programmes that could aid market expansion.

    3. Machine Learning Modelling

      • We integrated over 200 variables—from average selling prices (ASPs) to competitor moves, procedure frequency, and reimbursement model structures—into a feature set.
      • Our machine learning model produced a dynamic forecast of the potential market shift, competitor responses, and the optimal price point for the new device.

    4. Independent Validation of Price & Market Size

      • Once the model insights were distilled, we discovered that the market size was smaller and more complex than the original estimate by the consulting firm.
      • Critically, our analysis suggested an 8% premium over the previously recommended price, indicating a stronger willingness-to-pay (and better coding pathways) than initially anticipated.

    Results

    1. Strategic Pricing Realignment

      • Armed with data-driven evidence, the scale-up opted to set a higher price point than originally planned.
      • They successfully negotiated reimbursement at this premium level, reinforcing the perceived value of the innovative device.

    2. Rapid Market Capture

      • Within the first six months post-launch, the company secured 23% market share in its specialised domain—an impressive feat for a new entrant with a niche application.

    3. Enhanced Competitive Positioning

      • Insights gleaned from the machine learning model not only shaped the initial launch strategy but also continue to inform broader positioning with specialists, payers, and providers.
      • The scale-up can now proactively respond to market shifts, competitor activity, and new funding opportunities.

    4. Ongoing Data-Driven Culture

      • Having seen tangible results, the organisation has embraced an AI-led approach for ongoing market intelligence, using real-time data to guide future product rollouts and expansions.

    Conclusion

    This case study underscores the power and importance of AI-driven market intelligence. By combining large-scale data aggregation with primary research and machine learning, Vamstar helped a MedTech scale-up refine its strategy in near-record time. Our independent validation revealed a viable price premium and provided a more accurate picture of the evolving market—enabling the company to secure reimbursement, claim market share rapidly, and maintain a competitive edge.

     

    In today’s rapidly shifting healthcare landscape, traditional consulting methods can be bolstered significantly by AI. The ability to gather, structure, and analyse vast swathes of market data in real time ensures that commercial teams remain one step ahead, launching products at the right price point and capturing untapped opportunities faster. As this scale-up’s story proves, embracing AI-led insights is a strategic imperative for organisations striving to excel in dynamic, high-stakes markets.

    Why Market Intelligence is Critical for MedTech Success

    Making informed, timely decisions can spell the difference between a blockbuster device launch and a costly flop. The risks of outdated or incomplete market data are very real for MedTech companies. Relying on yesterday’s insights can lead to misallocating resources or targeting the wrong customer segments. Studies have found that clinging to static pricing and market assumptions can erode significant value – companies may be leaving up to 22% of potential revenue on the table due to outdated strategies. Likewise, insufficient intelligence on the reimbursement landscape or hospital purchasing trends can result in painful missteps, like focusing on a market that isn’t ready or losing ground to a better-informed competitor.

    Comprehensive (AI Led) market intelligence mitigates these risks by equipping MedTech leaders with a 360° view of the environment.

    Several data pillars are essential:

    • Regulatory insights: Staying ahead of approval requirements and policy changes in each target region. For example, tracking upcoming FDA or EU MDR regulatory changes ensures no surprises in the go-to-market timeline. For example, tracking upcoming national or international regulatory changes and the registration requirements and timelines in specific countries ensures no surprises in the go-to-market timeline.
    • Pricing and reimbursement trends: Understanding how payers are behaving – from Medicare’s coverage decisions to hospitals’ price sensitivity. This helps in setting pricing strategies that meet profit goals while remaining competitive and justifiable to purchasers.
    • Competitor tracking: Continuous monitoring of competitor moves, pipeline products, and partnerships. Market intelligence can alert teams to new entrants or Merger and Acquisition activity that could reshape the competitive landscape.
    • Demand signals: Capturing indicators of market demand in real time, such as procurement tenders, volume of relevant procedures, or emerging patient demographics. These signals help predict where the next growth opportunities will be.

    Failing to have clarity on any of these fronts can undermine a product’s success. As one industry CEO observed, startups especially “don’t have the resources or runway to withstand missteps like targeting the wrong markets or negotiating extended reviews from value analysis committees”. In contrast, precise market intelligence gives much-needed direction, showing MedTech teams where to focus and how to adjust their strategy.

    It enables data-driven answers to critical questions: Which patient sub-populations are most likely to benefit? Which regions are seeing uptake of similar technologies? Who are the key decision-makers to engage at target hospitals? Armed with current, granular data, commercialisation teams can optimise their launch plans and course-correct quickly if market feedback changes. In sum, robust market intelligence isn’t a ‘nice-to-have’ – it is a strategic necessity for MedTech companies aiming to successfully bring life-changing innovations to patients.

    How AI is Revolutionising Market Intelligence

    AI technologies are enabling MedTech leaders to interact with market data in powerful new ways. Instead of static reports, executives can leverage dynamic dashboards and real-time analytics to inform their decisions.

    AI is fundamentally transforming how market intelligence is gathered and used. Traditional business intelligence might update monthly or quarterly, but AI-driven platforms deliver real-time insights by continuously scouring and analysing data from a multitude of sources. This means a MedTech commercialisation team can receive instant alerts about relevant changes – from a competitor’s product approval to a surge in procurement tenders for their device category.

    The days of “drowning in volumes of disparate data” are fading. AI systems excel at aggregating big data and filtering the noise for what matters, reducing the manual burden on staff and ensuring no critical signal is missed. For example, AI can automatically monitor global tender databases, news feeds, regulatory announcements, and even clinician sentiment on social media, then synthesise that into concise intelligence for the team.

    Beyond monitoring, AI brings predictive analytics into play. Machine learning algorithms can identify patterns and correlations in historical and real-world data that humans might overlook. This enables forecasting of market trends with a new level of accuracy – such as predicting which regions will see the highest procedure growth next quarter, or which hospitals are most likely to adopt a new technology early. In one instance, a MedTech firm used predictive models to anticipate demand in high-volume regions and strategically placed sales reps there, rather than following the traditional flat territory model. The result was faster uptake and more efficient use of their commercial resources. AI essentially allows companies to simulate “what if” scenarios (e.g., how would a 5% price drop affect market share? which competitor is likely to bid aggressively in a tender?) and prepare in advance with data-backed strategies.

    Another game-changer is agentic automation of labour-intensive intelligence tasks. AI can now perform in seconds what might take an analyst weeks. For instance, Vamstar’s AI engines have been used to automatically scrape and analyse thousands of sources – individual company websites, financial filings, conference abstracts, and even LinkedIn data – to map out an entire sub-market for opportunities. This level of comprehensive analysis, including forecasting each competitor’s revenues and market share, was previously unattainable at speed. By automating data collection and number-crunching, AI frees up human experts to focus on interpretation and strategy.

    Notably, the best outcomes occur when AI insights are combined with human expertise, as AI can occasionally generate spurious correlations (“hallucinations”) that seasoned analysts must vet. Many leading solutions therefore pair AI analytics with expert review to ensure recommendations are accurate and actionable. A practical grasp of healthcare market intelligence principles is essential to effectively leveraging AI, such as the concepts covered in the Foxfire Masterclass.

    Case in point: Profound Medical, a MedTech innovator in prostate therapy, leveraged an AI-powered market intelligence platform to supercharge its commercialisation. The company’s success wasn’t just due to their novel product; it was how they used data to target the market. Profound mapped out “everyone involved in the patient journey – surgeons, imaging specialists, outpatient facilities” for prostate care. AI-driven analysis revealed which physicians performed high volumes of relevant procedures and which regions had clusters of untreated patients. With these insights, Profound strategically focused its outreach on the most influential surgeons and centers, and even hired sales reps based on market needs rather than geography, saving on unnecessary positions.

    As their Chief Commercial Officer noted, the data allowed them to understand precisely where their markets are and expand from a position of strength. This example illustrates how AI-powered intelligence can pinpoint opportunities, optimise resource allocation, and accelerate product adoption in MedTech.

    In broader terms, AI is enabling MedTech companies to be more proactive and precise. Instead of reacting to market events after the fact, firms can anticipate and prepare. AI’s predictive power and speed are like having a compass in the fog of the healthcare market. One Vamstar analysis highlighted how applying AI to tender and RFP processes can even reveal insights into competitor net pricing and market trends that were previously hidden, allowing companies to respond with agility. Such capabilities mark a leap beyond what manual analysis could achieve. As a McKinsey report put it, MedTech organisations now have access to more data and advanced analytics than ever, and these are being deployed to address an “ever-widening range of commercial challenges” from customer micro-segmentation to bid price optimisation. AI is truly revolutionising market intelligence by delivering the right information to the right people at the right time – and often before anyone else even knows there’s an opportunity or threat emerging.

    Practical Steps to Leverage AI in MedTech Commercialisation

    Embracing AI-powered market intelligence may seem like a daunting task, but there are concrete steps and tools that MedTech commercialisation teams can take today. Below are practical steps to get started and integrate AI-driven insights into strategic decision-making:

    1. Audit Your Data and Intelligence Gaps: Begin by assessing what market data you currently collect (e.g., sales reports, third-party market research including data provide by current distributors) and where the blind spots are. Identify questions you struggle to answer with confidence – for example, “Which competing devices are in the pipeline?” or “How are procurement patterns changing in my segment?” This gap analysis will clarify your priorities for an AI solution.
    2. Explore AI-Driven Intelligence Platforms: Look into tools that aggregate and analyse healthcare market data using AI. Modern platforms (such as Vamstar’s Polaris or others) offer data orchestration features to pull in diverse sources – regulatory databases, tenders, news, clinical trial results, etc. – into one view. They often include machine learning analytics and predictive modelling out-of-the-box. When evaluating solutions, consider capabilities like real-time alerting, customisable dashboards, and the specific data coverage for MedTech. Ensure the platform covers your target geographies and device categories with high-quality, up-to-date data.
    3. Leverage Specific AI Tools for Key Tasks: In addition to broad platforms, there are targeted AI tools that can boost particular aspects of commercialisation. For instance:
      1. Pricing optimisation AI – to analyse market pricing, reimbursement rates, and suggest optimal pricing strategies for your device (Vamstar’s Pricing Co-Pilot is one example).
      2. Regulatory intelligence AI – to track and summarise global regulatory changes or approval status of devices similar to your product registration requirements and timelines.
      3. Competitive intelligence bots – AI agents that monitor competitor news, patents, clinical trial registrations, and flag relevant updates.
      4. Demand forecasting models – using hospital procedure data and epidemiological trends to predict future demand for your product. Many of these tools use advanced algorithms but present insights in intuitive visualisations or plain language. They can often be piloted on a limited scope before a wider roll-out.
    4. Integrate AI Insights into Decision Processes: To get real value, AI-generated insights must be embedded into your team’s day-to-day decision-making. This may involve integrating the AI platform with your CRM or analytics software so that, for example, a sales rep sees actionable intelligence (like a hot new lead or a change in a hospital’s buying behaviour) right inside their workflow. Ensure your marketing and sales meetings incorporate AI reports – e.g. a weekly “market pulse” briefing from the platform. Over time, this makes data-driven thinking the norm. It’s also wise to train your team on interpreting AI outputs: understanding confidence levels, basic data science concepts, and knowing when to seek an expert’s interpretation.
    5. Start Small, Then Scale Up: Identify a high-impact use case to pilot AI. This could be something like “improve our win rate in hospital tenders” or “identify 100 new surgeon targets for our device.” By focusing on one area, you can configure the AI tools, get quick wins, and build internal buy-in. As McKinsey experts advise, avoid waiting for the perfect data or perfect tool – start with a reasonable scope and iterate. Early success will justify expanding AI to other facets of commercialisation. Many companies find that initial projects not only deliver results (for instance, a notable jump in lead conversions or time saved on research) but also help the team learn how to collaborate with AI systems effectively.
    6. Engage Experts and Partners: Finally, don’t go it alone. Tap into expert consultation to tailor AI solutions to your unique needs. This could mean working with your chosen platform’s data scientists or consultants to configure models for your product category. It might also involve partnering with a firm like Vamstar that specialises in AI for life sciences. As we’ll discuss, having a partner with deep domain expertise can accelerate your AI adoption and ensure it truly aligns with your strategic goals.

    By following these steps, MedTech commercialisation teams can gradually but steadily incorporate AI into their market strategy process. The key is to treat AI-driven intelligence not as a magic box, but as a strategic asset that your team learns to wield. With the right tools and integration, even companies new to AI can start making more informed decisions within weeks, positioning themselves to outpace competitors in the race for market share.

    Actionable Takeaways & Next Steps

    In today’s fast-evolving MedTech arena, leveraging AI for market intelligence is no longer optional – it’s a defining factor for success.

    To summarise the key insights from this paper:

    1. AI addresses critical commercialisation challenges: It helps overcome regulatory complexity, pricing pressures, and data overload by providing real-time, filtered insights. Companies that use AI can anticipate market changes instead of just reacting to them.
    2. The cost of inaction is high: Relying on outdated or siloed data can lead to missed opportunities and lost revenue. In fact, static approaches to pricing and market strategy have been shown to forfeit as much as one-fifth of potential value. Effective market intelligence is a competitive necessity, not a luxury.
    3. AI delivers proven benefits: Early adopters in MedTech have seen dramatic improvements such as higher lead conversion rates and incremental revenue growth. Case studies show faster product adoption when AI guides targeting and resource allocation.
    4. Human expertise remains vital: AI is a force-multiplier for your team, not a replacement. The strongest approach is combining AI analytics with the strategic intuition of your experts to validate insights and drive decisions.
    5. Start now and scale gradually: The most successful firms begin applying AI to priority use cases without delay, learning and expanding as they go. Those who wait for a “perfect” solution risk being left behind in a fast-moving market.

    With these points in mind, here are next steps your organisation can take to kickstart AI-powered market intelligence:

    • Champion a pilot project. Identify a pressing challenge (e.g., understanding a new market segment) and task a small team to evaluate an AI intelligence tool against it. Set clear metrics (number of new insights, time saved, etc.) to measure success.
    • Invest in training and change management. Begin by establishing a foundational understanding of healthcare market intelligence principles across your teams—particularly essential for those recruited from outside healthcare, as the industry’s dynamics differ significantly from other sectors. Equip your commercialisation and marketing teams with robust data literacy training and proficiency in new AI tools, emphasising how these capabilities will enable them to achieve greater impact and avoid costly learning curves.
    • Consult with experts. Arrange a workshop or demo with an AI in MedTech specialist (for example, Vamstar’s consulting team) to explore tailored solutions for your business. An expert perspective can highlight quick wins and avoid common pitfalls in implementation.
    • Iterate and integrate. Use feedback from the pilot to refine your approach and then integrate the AI solution into broader commercial planning. This might mean linking it with CRM systems, setting up regular intelligence reports for leadership, and expanding the data sources it covers.
    • Stay agile and informed. AI and market conditions will both continue to evolve. Plan periodic reviews of your market intelligence strategy – what new data could be incorporated? what new AI features are available? Maintain a mindset of continuous improvement.

    By taking these steps, MedTech executives and commercialisation teams can confidently embark on the AI journey. The payoff is a smarter, more responsive organisation that can navigate market complexities with clarity.

    About Vamstar

    Vamstar is a leading partner for MedTech companies seeking to harness AI-driven market intelligence. Unlike generalist AI providers, Vamstar is exclusively focused on the life sciences and healthcare sector, bringing deep domain expertise to every solution. Our flagship platform, Polaris AI, is an advanced data integration, analytics, and predictive modelling solution designed to break down data silos and turn raw healthcare market data into actionable insights. From real-time tender tracking and pricing intelligence to market access analytics, Vamstar’s tools are built to address the specific needs of MedTech and Pharma organisations on a global scale.

    What sets Vamstar apart is not only our cutting-edge technology but also our team’s extensive industry experience – over 75 years of combined expertise in MedTech, Pharma, commercial and procurement domains. We understand the nuances of regulatory environments, procurement processes, and commercial strategy in healthcare. This means we don’t just deliver data; we deliver context and guidance. Our data scientists and consultants work hand-in-hand with your team to tailor AI models to your product portfolio and market challenges, ensuring that insights align with your business goals.

    Vamstar’s solutions have helped clients achieve results such as identifying high-value market opportunities, optimising pricing to improve margins, helping companies launch new products and solutions in key markets, and even guiding successful acquisitions through AI-driven analysis. We pride ourselves on setting new standards in how market intelligence is used to drive growth and innovation in the healthcare sector.

    If you’re ready to elevate your commercialisation strategy with AI, we invite you to engage with our experts. Whether it’s a personalised demo of our Polaris platform, a strategy workshop to explore use cases, or a full-scale pilot project, our team is here to support your journey. The question for MedTech leaders today is no longer whether to implement AI, but who to trust for effective deployment. With Vamstar as your partner, you gain a trusted advisor dedicated to unlocking the competitive advantages of AI for your organisation.

    To learn more about how Vamstar can empower your market entry and growth with AI-powered intelligence, contact us for an expert consultation. Visit our website or reach out to schedule a demo and discussion tailored to your needs. Let us help you transform data into decisive action and chart a course for commercial success in the new era of MedTech. Your next breakthrough in market insight is just a conversation away – connect with Vamstar and let’s shape the future of MedTech commercialisation together.

    Empower Your Market Entry

    To learn more about how Vamstar can empower your market entry and growth with AI-powered intelligence, contact us for an expert consultation.

    Contact Us

    About Foxfire Academy and the Masterclass: Medical Device Distribution

    Foxfire MedTech Academy offers one of the most focused and impactful training platforms available to MedTech organisations aiming to master the intricacies of medical device distribution. Purpose-built for the sector, Foxfire goes beyond generic sales training by addressing the commercial, regulatory, and operational complexities unique to MedTech — drawing on over three decades of experience across R&D, ISO 13485, MDR/IVDR compliance, international sales, and distribution strategy.

    At the core of their offering is the Masterclass: Medical Device Distribution — a structured, outcomes-driven programme designed to help MedTech companies design, implement, and scale high-performing distributor networks. This masterclass equips teams with the practical tools and frameworks needed to avoid common pitfalls, optimise distributor performance, and accelerate go-to-market execution across diverse geographies.

    Through a combination of expert-led training, strategic coaching, and a peer-supported learning community, Foxfire helps MedTech organisations to:

    • Identify and onboard the right distribution partners
    • Shorten sales cycles and improve forecasting accuracy
    • Drive better performance and accountability across markets
    • Strengthen regulatory and commercial compliance
    • Achieve more predictable, scalable revenue growth

    Partnering with Foxfire MedTech Academy

    Vamstar recognises the strategic importance of distributor excellence in MedTech commercialisation. For teams looking to improve market access execution, Foxfire MedTech Academy provides access to a proven, repeatable model for success. Whether you’re seeking a comprehensive training programme, a decision-making framework for distributor selection, or expert input on scaling effectively, Foxfire offers a highly targeted solution to meet your needs.

    To explore how Foxfire MedTech Academy can support your growth and expansion plans, book a complimentary strategy call or gain access to a preview session of their flagship Masterclass. Learn more via their website — and unlock the next stage of your global commercial journey.

    Exclusive Resource

    This white paper has been co-authored by Vamstar and Foxfire MedTech. Elements of the content are also featured in the Masterclass: Medical Device Distribution by the Foxfire Academy. The intellectual property within this document is jointly copyrighted by Vamstar and Foxfire MedTech. Any reproduction, distribution, or use of this material, in whole or in part, requires prior written consent from both parties.

    ©Vamstar & Foxfire MedTech